These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 19616334)

  • 1. Binding of cetuximab to the EGFRvIII deletion mutant and its biological consequences in malignant glioma cells.
    Jutten B; Dubois L; Li Y; Aerts H; Wouters BG; Lambin P; Theys J; Lammering G
    Radiother Oncol; 2009 Sep; 92(3):393-8. PubMed ID: 19616334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface.
    Patel D; Lahiji A; Patel S; Franklin M; Jimenez X; Hicklin DJ; Kang X
    Anticancer Res; 2007; 27(5A):3355-66. PubMed ID: 17970081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The deletion mutant EGFRvIII significantly contributes to stress resistance typical for the tumour microenvironment.
    Theys J; Jutten B; Dubois L; Rouschop KM; Chiu RK; Li Y; Paesmans K; Lambin P; Lammering G; Wouters BG
    Radiother Oncol; 2009 Sep; 92(3):399-404. PubMed ID: 19616331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
    Lammering G; Hewit TH; Holmes M; Valerie K; Hawkins W; Lin PS; Mikkelsen RB; Schmidt-Ullrich RK
    Clin Cancer Res; 2004 Oct; 10(19):6732-43. PubMed ID: 15475464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
    Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling.
    Hasselbalch B; Lassen U; Poulsen HS; Stockhausen MT
    Cancer Invest; 2010 Oct; 28(8):775-87. PubMed ID: 20504227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
    Bax DA; Gaspar N; Little SE; Marshall L; Perryman L; Regairaz M; Viana-Pereira M; Vuononvirta R; Sharp SY; Reis-Filho JS; Stávale JN; Al-Sarraj S; Reis RM; Vassal G; Pearson AD; Hargrave D; Ellison DW; Workman P; Jones C
    Clin Cancer Res; 2009 Sep; 15(18):5753-61. PubMed ID: 19737945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III.
    Fukai J; Nishio K; Itakura T; Koizumi F
    Cancer Sci; 2008 Oct; 99(10):2062-9. PubMed ID: 19016767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
    Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
    Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.
    Lorimer IA; Wikstrand CJ; Batra SK; Bigner DD; Pastan I
    Clin Cancer Res; 1995 Aug; 1(8):859-64. PubMed ID: 9816055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation.
    Wang H; Shi B; Zhang Q; Jiang H; Hu S; Kong J; Yao M; Yang S; Li Z
    FASEB J; 2012 Jan; 26(1):73-80. PubMed ID: 21917986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.
    Wikstrand CJ; McLendon RE; Friedman AH; Bigner DD
    Cancer Res; 1997 Sep; 57(18):4130-40. PubMed ID: 9307304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
    Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
    Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
    Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
    Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII.
    Aerts HJ; Dubois L; Hackeng TM; Straathof R; Chiu RK; Lieuwes NG; Jutten B; Weppler SA; Lammering G; Wouters BG; Lambin P
    Radiother Oncol; 2007 Jun; 83(3):326-32. PubMed ID: 17531336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of collapsin response mediator Protein1, as detected by iTRAQ analysis, promotes invasion of human gliomas expressing mutant EGFRvIII.
    Mukherjee J; DeSouza LV; Micallef J; Karim Z; Croul S; Siu KW; Guha A
    Cancer Res; 2009 Nov; 69(22):8545-54. PubMed ID: 19903856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
    Wikstrand CJ; Hale LP; Batra SK; Hill ML; Humphrey PA; Kurpad SN; McLendon RE; Moscatello D; Pegram CN; Reist CJ
    Cancer Res; 1995 Jul; 55(14):3140-8. PubMed ID: 7606735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo.
    Arwert E; Hingtgen S; Figueiredo JL; Bergquist H; Mahmood U; Weissleder R; Shah K
    Cancer Res; 2007 Aug; 67(15):7335-42. PubMed ID: 17671203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.